Integrated Investment Consultants LLC Sells 1,812 Shares of CONMED Co. (NYSE:CNMD)

Integrated Investment Consultants LLC cut its position in shares of CONMED Co. (NYSE:CNMD) by 37.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,055 shares of the company’s stock after selling 1,812 shares during the quarter. Integrated Investment Consultants LLC’s holdings in CONMED were worth $209,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of CNMD. GAMMA Investing LLC lifted its stake in CONMED by 93.6% in the fourth quarter. GAMMA Investing LLC now owns 726 shares of the company’s stock worth $50,000 after purchasing an additional 351 shares during the last quarter. CWM LLC increased its holdings in shares of CONMED by 36.1% in the third quarter. CWM LLC now owns 1,251 shares of the company’s stock worth $90,000 after buying an additional 332 shares during the period. nVerses Capital LLC lifted its stake in shares of CONMED by 566.7% in the 3rd quarter. nVerses Capital LLC now owns 2,000 shares of the company’s stock valued at $144,000 after acquiring an additional 1,700 shares during the last quarter. Federated Hermes Inc. purchased a new stake in CONMED during the 2nd quarter valued at about $167,000. Finally, ZWJ Investment Counsel Inc. bought a new position in CONMED during the 3rd quarter worth approximately $206,000.

Analyst Ratings Changes

Several brokerages have weighed in on CNMD. StockNews.com downgraded CONMED from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Needham & Company LLC reiterated a “buy” rating and set a $97.00 price target on shares of CONMED in a report on Thursday, October 31st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, CONMED has a consensus rating of “Moderate Buy” and an average price target of $79.80.

CONMED Price Performance

CNMD opened at $67.75 on Friday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.06 and a current ratio of 2.27. The stock has a market capitalization of $2.09 billion, a PE ratio of 16.09, a price-to-earnings-growth ratio of 0.74 and a beta of 1.47. The stock’s 50 day moving average price is $71.29 and its 200-day moving average price is $70.03. CONMED Co. has a 52-week low of $61.05 and a 52-week high of $110.40.

CONMED (NYSE:CNMD) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.99 by $0.06. The business had revenue of $316.70 million for the quarter, compared to the consensus estimate of $318.46 million. CONMED had a net margin of 10.23% and a return on equity of 13.84%. On average, equities research analysts predict that CONMED Co. will post 4.03 EPS for the current year.

CONMED Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 3rd. Stockholders of record on Friday, December 20th were given a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 1.18%. The ex-dividend date of this dividend was Friday, December 20th. CONMED’s dividend payout ratio is currently 19.00%.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.